Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices? - PubMed (original) (raw)
Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?
Robert E Becker et al. J Clin Psychopharmacol. 2009 Feb.
Abstract
Evidence-based psychiatry seeks the best research evidence for use in patient care. Recent research suggests that problems with accuracy, precision, bias, and other sources of unreliability potentially interfere with the validity of psychiatry's evidence base. Because many negative clinical research studies go unpublished, awareness and fuller understanding of these problems are blocked by lack of access to relevant data. Based on the importance of scientific soundness of neuropsychiatric research and patient care, we argue for increased attentiveness by investigators and practitioners to how clinical trials (CTs) interdependently estimate the efficacy of treatments and the effectiveness of methods as fair tests of efficacy. Deference by CT investigators to real-world practice conditions at research sites because of the unreliability introduced into data by these practices does not ensure unbiased evaluations of treatment efficacy. We argue for more systematic attention to sources of unreliability in CT investigations and increased commitments to assure the validity of the neuropsychiatric evidence base. These recommendations aim to determine neuropsychiatric drug efficacy with greater certainty to better quantify the clinical importance of drug-associated effects and to provide CT-evidenced guidance for practitioners to most effectively use drug efficacy in patient care.
Conflict of interest statement
The authors have received no other funding for this work and have no financial conflicts of interest. The views expressed within this article are those of the authors and may not represent those of the National Institute on Aging, National Institutes of Health.
Similar articles
- Lost in translation: neuropsychiatric drug development.
Becker RE, Greig NH. Becker RE, et al. Sci Transl Med. 2010 Dec 8;2(61):61rv6. doi: 10.1126/scitranslmed.3000446. Sci Transl Med. 2010. PMID: 21148128 Free PMC article. Review. - Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Crider K, et al. Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article. - The future of Cochrane Neonatal.
Soll RF, Ovelman C, McGuire W. Soll RF, et al. Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834 - Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology. Higashida RT, et al. Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17. Stroke. 2003. PMID: 12869717 - A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G. Forbes C, et al. Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100 Review.
Cited by
- A new regulatory road-map for Alzheimer's disease drug development.
Becker RE, Greig NH. Becker RE, et al. Curr Alzheimer Res. 2014 Mar;11(3):215-20. doi: 10.2174/156720501103140329210642. Curr Alzheimer Res. 2014. PMID: 24694075 Free PMC article. Review. - Why so few drugs for Alzheimer's disease? Are methods failing drugs?
Becker RE, Greig NH. Becker RE, et al. Curr Alzheimer Res. 2010 Nov;7(7):642-51. doi: 10.2174/156720510793499075. Curr Alzheimer Res. 2010. PMID: 20704560 Free PMC article. Review. - Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?
Becker RE, Greig NH. Becker RE, et al. Alzheimers Dement. 2013 Jan;9(1):50-7. doi: 10.1016/j.jalz.2012.01.007. Epub 2012 Mar 30. Alzheimers Dement. 2013. PMID: 22465172 Free PMC article. - Lost in translation: neuropsychiatric drug development.
Becker RE, Greig NH. Becker RE, et al. Sci Transl Med. 2010 Dec 8;2(61):61rv6. doi: 10.1126/scitranslmed.3000446. Sci Transl Med. 2010. PMID: 21148128 Free PMC article. Review. - Advances in Alzheimer therapy: understanding pharmacological approaches to the disease.
Martínez A, Lahiri DK, Giacobini E, Greig NH. Martínez A, et al. Curr Alzheimer Res. 2009 Apr;6(2):83-5. doi: 10.2174/156720509787602924. Curr Alzheimer Res. 2009. PMID: 19355842 Free PMC article.
References
- Sackett DL, Strauss SE, Richardson WS, et al. Evidence-Based-Medicine: How to Practice and Teach EBM. New York, NY: Churchill-Livingstone; 2000.
- Gray GE, Pinson LA. Evidence-based medicine and psychiatric practice. Psychiatr Q. 2003;74:387–399. - PubMed
- Gupta M. Does evidence-based medicine apply to psychiatry? Theor Med Bioeth. 2007;28:103–120. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials